The United States Food and Drug Administration (FDA) has granted fast track designation to United States-based Proteostasis Therapeutics for its triple combination program to treat cystic fibrosis, it was reported yesterday.
The firm's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector and potentiator, called PTI-428, PTI-801 and PTI-808, respectively.
The company had previously announced that the protocol for its triple combination clinical study, which it plans to initiate in the current quarter, has received endorsement and a high strategic fit score from the Therapeutics Development Network and the Clinical Trial Network, the drug development arms of the Cystic Fibrosis Foundation and the European CF Society, respectively.
The FDA's fast track designation is designed to facilitate the development and accelerate the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical requirements.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial